The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) for resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Efficacy by surgical outcomes in the phase 3 KEYNOTE-689 trial.
 
Douglas Adkins
Consulting or Advisory Role - Adcendo; Adlai Nortye; AstraZeneca; Boehringer Ingelheim; CUE Biopharma; Genmab/Seattle Genetics; GlaxoSmithKline; Immunitas; InhibRx; Johnson & Johnson/Janssen; Kura Oncology; Merck; Merus; Purple Biotech; Pyxis; Regeneron; Tubulis GmbH
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); Coherus Biosciences (Inst); CUE Biopharma (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immutep (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Rgenta (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tempus (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst); Xilio Therapeutics (Inst)
 
Robert Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Stock and Other Ownership Interests - tosk
Consulting or Advisory Role - Abbvie; Abbvie; ALX Oncology; Astellas Pharma; AstraZeneca; aveo; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Eisai; EMD Serono; Genmab; Genzyme; GlaxoSmithKline; Johnson & Johnson/Janssen; Merck; PDS Biotechnology; RAPT Therapeutics; Scholar Rock
Research Funding - AstraZeneca (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); Merus (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; Hookipa Pharma; Incyte; ISA Pharmaceuticals; Nanobiotix
 
Yungan Tao
No Relationships to Disclose
 
Christophe Le Tourneau
Honoraria - Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Novartis; Rakuten Medical; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; MSD; Nanobiotix; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD
 
Nancy Lee
Consulting or Advisory Role - J and J; LEO SAB; Merck; Signatera
Research Funding - AstraZeneca (Inst)
 
William Westra
No Relationships to Disclose
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Genmab; GlaxoSmithKline; Janssen; Lilly; Merck KGaA; MSD; Nanobiotix; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Nanobiotix (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Kevin Harrington
Honoraria - Abbvie (Inst); ALX Oncology (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicara Therapeutics (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Flamingo Pharma (Inst); GlaxoSmithKline (Inst); Johnson and Johnson (Inst); Merck Serono (Inst); Merus (Inst); MSD (Inst); Nanobiotix (Inst); PDS Biotechnology (Inst); PsiVac Ltd (Inst); QBiotics (Inst); Replimune (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Onchilles Pharma (Inst); Replimune (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst)
 
Arkadiy Klochikhin
No Relationships to Disclose
 
Coro Bescos
No Relationships to Disclose
 
Gustavo Alves
Consulting or Advisory Role - AstraZeneca; Merck Serono; MSD Oncology
Speakers' Bureau - AstraZeneca; GlaxoSmithKline; Sanofi
Research Funding - AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BMS Brazil (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Roche (Inst); Sanofi (Inst); Zymeworks (Inst); Zymeworks (Inst)
 
Brett Hughes
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche; Sanofi/Aventis; Takeda
Speakers' Bureau - MSD Oncology
Research Funding - Amgen (Inst)
 
Marc Oliva
Honoraria - Merck; MSD Oncology
Consulting or Advisory Role - Merck KGaA; MSD Oncology; Obatica; Pyxis; Transgene
Research Funding - ALX Oncology (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Merck; MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
 
Iane Pinto Figueiredo Lima
No Relationships to Disclose
 
Tsutomu Ueda
Honoraria - Eisai; Meiji Seika Kaisha; Mitsubishi Tanabe Pharma; MSD; Novartis; Rakuten Medical Japan
Research Funding - Lilly Japan
 
Chih-Chin Liu
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Kimberly Benjamin
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
Travel, Accommodations, Expenses - Merck
 
Bin Zhao
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Ravindra Uppaluri
Consulting or Advisory Role - Daichi-Sankyo; Johnson & Johnson/Janssen; Merck; Regeneron
Research Funding - Daichi-Sankyo; Merck
Patents, Royalties, Other Intellectual Property - Washington University licenses mouse oral cancer cell lines made by my lab. I receive royalties from Washington University from these agreements.
Travel, Accommodations, Expenses - Merck
(OPTIONAL) Uncompensated Relationships - IO Biotech